INVITATION TO PRESENTATION OF FIRST QUARTER 2016 FINANCIAL RESULTS
NattoPharma will release its first quarter 2016 financial results on Friday 20 May 2016 at approximately 08:30 CET. The first quarter 2016 report will be made available at www.nattopharma.com and at www.oslobors.no.
The same day, starting at 10:00 am, the company will host a webcast with a presentation of the quarterly results, followed by an online Q&A session.
Please follow the below link to join the web-cast,
The presentation will be held by CEO Daniel H. Rosenbaum and CFO Kjetil Ramsøy.
For more information, please contact:
Mobil: +47 906 12 943
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
About NattoPharma and MenaQ7®
NattoPharma ASA, based in Norway, is the world's leader in vitamin K2 R&D. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, commercially available Vitamin K2 as MK-7 with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Metuchen, NJ.